Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018045145) SEROLOGIC ASSAY OF LIVER FIBROSIS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/045145 International Application No.: PCT/US2017/049563
Publication Date: 08.03.2018 International Filing Date: 31.08.2017
IPC:
C07K 14/805 (2006.01) ,G01N 33/68 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
795
Porphyrin- or corrin-ring-containing peptides
805
Haemoglobins; Myoglobins
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68
involving proteins, peptides or amino acids
Applicants:
GEORGETOWN UNIVERSITY [US/US]; 37th and O Streets, N.W. Washington, DE 20057, US
Inventors:
GOLDMAN, Radoslav; US
SANDA, Miloslav; US
Agent:
STEELE, Alan W.; US
BARTON, Steven, K.; US
ALTER, Scott; US
BARONE, Stephen, B.; US
STEELE, Alan, W.; US
Priority Data:
62/383,02002.09.2016US
Title (EN) SEROLOGIC ASSAY OF LIVER FIBROSIS
(FR) DOSAGE SÉROLOGIQUE DE FIBROSE HÉPATIQUE
Abstract:
(EN) Provided are in vitro serologic methods of assessing the presence of, and assessing the progression of, liver fibrosis in a subject. Also provided are methods of assessing efficacy of an agent for the treatment of liver fibrosis, and methods of treating liver fibrosis. The methods involve quantitatively measuring di-sialylated and mono-sialylated O-glycoforms of a peptide fragment of hemopexin (HPX) in a test serum sample obtained from a test subject, and comparing the measured amounts of di-sialylated and mono-sialylated O-glycoforms of the peptide fragment of hemopexin to a reference amount. In certain embodiments, the measuring is performed using LC-MS/MS-MRM (liquid chromatography/tandem mass spectrometry/multiple reaction monitoring). In certain embodiments, the measuring is performed using LC/MS3 (liquid chromatography with triple-stage mass spectrometric detection).
(FR) L'invention concerne des procédés sérologiques in vitro pour l'évaluation de la présence de, et l'évaluation de la progression de la fibrose hépatique chez un sujet. L'invention concerne également des procédés d'évaluation de l'efficacité d'un agent pour le traitement de la fibrose hépatique, et des procédés de traitement de la fibrose hépatique. Les procédés impliquent la mesure quantitative de O-glycoformes di-sialylées et mono-sialylées d'un fragment peptidique d'hémopexine (HPX) dans un échantillon de sérum d'essai obtenu à partir d'un sujet d'essai, et à comparer les quantités mesurées de O-glycoformes di-sialylées et mono-sialylées du fragment peptidique d'hémopexine à une quantité de référence. Dans certains modes de réalisation, la mesure est effectuée à l'aide de LC-MS/MS-MRM (chromatographie liquide/spectrométrie de masse en tandem/surveillance de réaction multiple) Dans certains modes de réalisation, la mesure est effectuée à l'aide de LC/MS3 (chromatographie liquide avec détection par spectrométrie de masse à trois étages).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)